Eveglip-M Tablet is a combination oral antidiabetic medication containing Metformin 500mg and Vildagliptin 50mg, designed to improve glycemic control in adults with type 2 diabetes mellitus. Metformin, a biguanide, primarily works by decreasing hepatic glucose production and enhancing insulin sensitivity, thereby improving peripheral glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner, helping to regulate blood sugar levels effectively. The synergistic action of these two agents helps in achieving better glycemic control compared to monotherapy, reducing fasting and postprandial blood glucose levels. Eveglip-M is typically prescribed when diet, exercise, and monotherapy with either agent do not provide adequate glycemic control. It is important to use this medication under medical supervision, as it may cause side effects such as gastrointestinal disturbances, hypoglycemia, or rare cases of lactic acidosis. Regular monitoring of blood glucose and renal function is recommended during therapy. Eveglip-M Tablet offers a convenient and effective option for managing type 2 diabetes, supporting improved patient adherence and metabolic outcomes.